Market revenue in 2023 | USD 119.0 million |
Market revenue in 2030 | USD 168.0 million |
Growth rate | 5.1% (CAGR from 2023 to 2030) |
Largest segment | Percutaneous thrombectomy devices |
Fastest growing segment | Neurovascular Embolectomy Devices |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurovascular Embolectomy Devices, Embolectomy Balloon Catheters, Percutaneous Thrombectomy Devices, Catheter-directed thrombolysis (CDT) devices, Inferior vena cava filters (IVCF) |
Key market players worldwide | Medtronic PLC, Boston Scientific Corp, Teleflex Inc, Edwards Lifesciences Corp, LeMaitre Vascular Inc, Cook Medical, DePuy Synthes, iVascular, Vascular Solutions |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clot management devices market will help companies and investors design strategic landscapes.
Percutaneous thrombectomy devices was the largest segment with a revenue share of 36.13% in 2023. Horizon Databook has segmented the Germany clot management devices market based on neurovascular embolectomy devices, embolectomy balloon catheters, percutaneous thrombectomy devices, catheter-directed thrombolysis (cdt) devices, inferior vena cava filters (ivcf) covering the revenue growth of each sub-segment from 2018 to 2030.
Germany has a well-established healthcare system and infrastructure that supports the availability and accessibility of clot management devices. The country's robust healthcare system focuses on quality care and patient safety, which facilitates the use of advanced medical technologies and devices such as clot management devices.
As per the Commonwealth Fund article, an estimated 86% of the German population is covered by statutory health insurance, while the remaining have private substitutive coverage. Moreover, the country has regulatory mechanisms that lead to rapid market approval and cost effective clinical research for medical devices such as clot management.
Moreover, clot management devices need to have a CE mark to be sold in the country and they are generally classified under Class III owing to their high risk & invasive nature. Moreover, the emergence of COVID-19 led to an increase in the incidence of thrombosis across the globe & in Germany.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany clot management devices market , including forecasts for subscribers. This country databook contains high-level insights into Germany clot management devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account